|
Orthologous residues
|
|
MeCP2 (human): S423‑p, MeCP2 (mouse): S421‑p, MeCP2 iso2 (mouse): S438‑p, MeCP2 (rat): S421‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
electrophoretic mobility shift, mass spectrometry, mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
'neuron, cortical', 293T (epithelial), brain
|
|
Cellular systems studied:
cell lines, tissue
|
|
Species studied:
human, mouse, rat
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
CAMK2A (mouse)
|
phospho-antibody, pharmacological activator of upstream enzyme, transfection of dominant-negative enzyme, pharmacological inhibitor of upstream enzyme, transfection of constitutively active enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
KCl
|
|
|
|
increase
|
|
|
KN-93
|
KCl
|
|
|
inhibit treatment-induced increase
|
|
|
KN-92
|
KCl
|
|
|
no effect upon treatment-induced increase
|
|
|
glutamate
|
|
|
|
increase
|
|
|
nimodipine
|
glutamate
|
|
|
inhibit treatment-induced increase
|
|
|
APV
|
glutamate
|
|
|
inhibit treatment-induced increase
|
|
|
CNQX
|
glutamate
|
|
|
inhibit treatment-induced increase
|
|
|
EGTA
|
glutamate
|
|
|
inhibit treatment-induced increase
|
|
|
NMDA
|
|
|
|
increase
|
|
|
APV
|
NMDA
|
|
|
inhibit treatment-induced increase
|
|
|
EGTA
|
NMDA
|
|
|
inhibit treatment-induced increase
|
|
|
nimodipine
|
NMDA
|
|
|
inhibit treatment-induced increase
|
|
|
KN-93
|
NMDA
|
|
|
inhibit treatment-induced increase
|
|
|
KN-92
|
NMDA
|
|
|
no effect upon treatment-induced increase
|
|
|
bicuculline
|
|
|
|
increase
|
|
|
nimodipine
|
bicuculline
|
|
|
inhibit treatment-induced increase
|
|
|
APV
|
bicuculline
|
|
|
inhibit treatment-induced increase
|
|
|
CNQX
|
bicuculline
|
|
|
inhibit treatment-induced increase
|
|
|
BDNF
|
|
|
|
increase
|
|
|
EGF
|
|
|
|
no change compared to control
|
|
|
IGF-1
|
|
|
|
no change compared to control
|
|
|
NGF
|
|
|
|
no change compared to control
|
|
|
|
|
|
|
increase
|
NT3
|
|
|
|
|
|
increase
|
NT4
|
|
PDGF
|
|
|
|
no change compared to control
|
|
|
|
|
|
|
no change compared to control
|
CNTF
|
|
|
|
|
|
increase
|
Metrazole (pentylenetetrazole)
|
|
kainic acid
|
|
|
|
increase
|
|
|
light
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
activation
|
|
Effect of modification (process):
cell differentiation, altered, transcription, altered
|